ClinicalTrials.gg
CompletedNCT06987851Updated May 23, 2025

An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCAD

A Phase 3 interventional study of Divozilimab in Multiple Sclerosis, sponsored by Biocad. Completed at 15 sites in Russian Federation. Per ClinicalTrials.gov, last updated 2025-05-23.

Sponsored by Biocad · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 1 month after the study started (first participant enrolled Mar 2022, registered May 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 86 studies in Multiple Sclerosis with a site in Russian Federation — none open to participants now, none under way, none of them phase 3. Multiple Sclerosis · Russian Federation.

Enrollment
75th of 83
44 · median 402
Started
2022
the only one that year
Phase 3
40 of 86
none open now
Registered
86th of 86
by date
Lead sponsor
5 of 86
Biocad

Among the 86 studies in Multiple Sclerosis with a site in Russian Federation, this one is the 75th largest by enrollment of the 83 interventional ones that give a count, is the only one that started in 2022, is one of 40 in phase 3, and was the 86th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

None of the 86 studies in Multiple Sclerosis with a site in Russian Federation is open now. The open studies under Multiple Sclerosis, anywhere →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 86 studies in Multiple Sclerosis with a site in Russian Federation as a file.
02

Study summary

The aim of this clinical study is to assess the long-term efficacy and safety of BCD-132 (divozilimab) in patients with multiple sclerosis who previously participaded in BCD-132-2 and BCD-132-4/MIRANTIBUS studies

Read the detailed description

Clinical study BCD-132-EXT is a Phase III study extension conducted after completion of BCD-132 500 mg therapy by subjects of clinical studies BCD-132-2 and BCD-132-4/MIRANTIBUS.

The study is designed as a multicenter, open-label, non-randomized, non-comparative, single-arm clinical study.

The study consists of a screening period (14 days), a treatment period (96 weeks) and a follow-up period (4 weeks). During treatment period, the subjects will receive the investigational product BCD-132 (divozilimab).

The duration of participation for each subject will be approximately 102 weeks.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • multiple sclerosis, relapsing multiple sclerosis, anti-CD20, DMT, divosilimab
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written of the subject to participate in the study has been obtained.
  • The subject was in the BCD-132 500 mg group in BCD-132-2, then transferred to BCD-132-4/MIRANTIBUS and completed it according to the Protocol (completed all scheduled study visits).
  • Last administration of BCD-132 in BCD-132-4/MIRANTIBUS was performed at least 22 weeks before the planned date of the first drug administration in this clinical study.

Exclusion criteria

Exclusion Criteria:

  • Heart failure ( class III/IV).
  • detected after completion of study BCD-132-4/MIRANTIBUS and prior to signing the to participate in this study, as well as conditions (acute and chronic) precluding further treatment and participation in the study in the Investigator's opinion.
  • Metabolic abnormalities according to blood chemistry (including increased creatinine, urea, , AST) and/or blood count abnormalities (including decreased white blood cell count, absolute lymphocyte count, , count, decreased concentration) identified at the screening and precluding further treatment and participation in the study in the Investigator's opinion.
  • Pregnancy, breastfeeding, or planned pregnancy at any time during the participation in the study and 48 weeks after the scheduled last administration of the product in this study.
  • Use, between the completion of participation in BCD-132-4/MIRANTIBUS and the signing of the informed consent for this study, of the following drugs: anti-B cell therapies (e.g., rituximab, ocrelizumab, abatacept, belimumab, ofatumumab, and others); alemtuzumab, daclizumab, teriflunomide, mitoxantrone, cladribine; cyclophosphamide, cyclosporine, azathioprine; mycophenolate mofetil, fingolimod and other sphingosine-1-phosphate (S1P) receptor modulators, natalizumab.
  • Known intolerance, including to any component of BCD-132, premedication drugs, or conditions in which the above drugs are in the Investigator's opinion.
  • Historical evidence of progressive multifocal leukoencephalopathy (PML).
  • Contraindications to MRI and the use of gadolinium-containing contrast agents, including, but not limited to, the presence of metal foreign bodies, artificial heart valves, electronic middle ear implants, pacemakers; allergies to gadolinium or gadolinium-containing contrast agents.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    BCD-132 (divozilimab)

    Intravenous infusion of BCD-132 every 24 weeks

    Biological: Divozilimab

Interventions

  • BiologicalDivozilimab

    Intravenous infusion of BCD-132 every 24 weeks

06

What researchers measure

Primary outcomes

  1. Annualized relapse rate

    Time frame: 48 and 96 weeks

Secondary outcomes

  1. Time to first relapse

    Time frame: 102 weeks

  2. Proportion of patients without confirmed relapses

    Time frame: 48 and 96 weeks

  3. Total number of T1 Gd+ lesions (per scan)

    Time frame: 48 and 100 weeks

  4. Proportion of patients without contrast-enhancing lesions

    Time frame: 48 and 100 weeks

  5. Proportion of patients without new or enlarging T2 lesions

    Time frame: 48 and 100 weeks

  6. Number of new or enlarged T2 lesions

    Time frame: 48 and 100 weeks

  7. Number of CUA (Combined Unique Active) lesions

    Total number of new contrast-enhancing T1 lesions and new T2 lesions or enlarged T2-weighted lesions without double counting on MRI (Combined Unique Active)

    Time frame: 48 and 100 weeks

  8. Changes over time in neurological deficit parameters according to the Expanded Disability Status Scale (EDSS)

    Time frame: 102 weeks

  9. Changes over time in Timed 25-Foot Walk Test

    Time frame: 102 weeks

  10. Changes over time in 9-Hole Peg Test

    Time frame: 102 weeks

  11. Changes over time in Symbol Digit Modalities Test (SDMT)

    Time frame: 102 weeks

  12. Changes over time in quality of life indicators assessed with the SF-36 questionnaire

    Time frame: 102 weeks

07

Study locations

15 sites
  • Vyacheslav Andreyevich Dudin
    Kirov, Russian Federation
  • Dmitry Vladimirovich Pokhabov
    Krasnoyarsk, Russian Federation
  • Ivan Aleksandrovich Shchukin
    Moscow, Russian Federation
  • Sergey Viktorovich Kotov
    Moscow, Russian Federation
  • Elena Vladimirovna Parshina
    Nizhny Novgorod, Russian Federation
  • Irina Aleksandrovna Sokolova
    Nizhny Novgorod, Russian Federation
  • Gennady Nikolayevich Mishin
    Pyatigorsk, Russian Federation
  • Yuri Vladimirovich Trinitatsky
    Rostov-on-don, Russian Federation
  • Zoya Aleksandrovna Goncharova
    Rostov-on-Don, Russian Federation
  • Irina Yevgenyevna Poverennova
    Samara, Russian Federation
  • Leonid Grigoryevich Zaslavsky
    St. Petersburg, Russian Federation
  • Natalya Agafonovna Totolyan
    St. Petersburg, Russian Federation
  • Valentina Mikhaylovna Alifirova
    Tomsk, Russian Federation
  • Stella Anatolyevna Sivertseva
    Tyumen, Russian Federation
  • Irina Vladimirovna Greshnova
    Ulyanovsk, Russian Federation
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in May 2024, 25 months.

Of 71 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's 25 months is below that.

Counting every sponsor, half of 96 studies reached it within 42 months; a quarter within 26 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2025
First posted
May 23, 2025
StartActual
Mar 22, 2022
Primary completionActual
May 16, 2024
CompletionActual
May 16, 2024
Last update
May 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06987851
Lead sponsor
Biocad
Responsible party
Sponsor
First posted
May 23, 2025
Start date
Mar 22, 2022
Primary completion
May 16, 2024
Completion
May 16, 2024
Last update
May 23, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Divozilimab

Start the discussion